Gale A E, Solomon E, Tao B S
Clin Allergy. 1980 Sep;10(5):527-33. doi: 10.1111/j.1365-2222.1980.tb02133.x.
This study tested the effectiveness of flunisolide in the treatment of children with seasonal allergic rhinitis. Thirty-five children between the ages of 5 and 14 years used an intransal preparation of either flunisolide (200 micrograms/day) or placebo for a 6-week double-blind parallel trial consisting of a 2-week baseline phase and a 4-week treatment phase, conducted during a period of 'high' pollen counts in Adelaide, South Australia. Flunisolide was effective in reducing four symptoms of hay fever: sneezing, stuffy nose, runny nose and eye itch. Sixty-four percent of the flunisolide-treated group and 33% of the placebo-treated group noted substantial or total control of their hay fever symptoms (P < 0.05). The effect of the intranasal administration of flunisolide on the pituitary-adrenal axis was monitored by performing plasma cortisol measurements (a.m. and p.m.) and 24-hr urinary free cortisol excretion studies for each patient. The data confirmed that 200 micrograms/day intranasal flunisolide does not suppress the pituitary-adrenal-axis in this young patient population.
本研究测试了氟尼缩松治疗儿童季节性变应性鼻炎的有效性。35名年龄在5至14岁之间的儿童在南澳大利亚阿德莱德花粉计数“高峰期”期间，使用氟尼缩松（200微克/天）鼻内制剂或安慰剂进行了为期6周的双盲平行试验，该试验包括一个为期2周的基线期和一个为期4周的治疗期。氟尼缩松在减轻花粉热的四种症状方面有效：打喷嚏、鼻塞、流鼻涕和眼痒。氟尼缩松治疗组64%的患者和安慰剂治疗组33%的患者表示花粉热症状得到了显著控制或完全控制（P<0.05）。通过对每位患者进行血浆皮质醇测量（上午和下午）和24小时尿游离皮质醇排泄研究，监测了鼻内给予氟尼缩松对垂体-肾上腺轴的影响。数据证实，200微克/天的鼻内氟尼缩松在该年轻患者群体中不会抑制垂体-肾上腺轴。
